Monday, May 08, 2023 7:33:01 PM
Press Release | 05/08/2023
Date : May 8, 2023
Global Pharma Labs, Inc. ("Labs") and GPL Holdings , Inc. ("GPLL") entered into a Letter of Intent to merge whereas the shareholders of Labs would become shareholders of GPLL. The resulting merger would result in Labs becoming awholly owned subsidiary of GPLL.
Additionally, Global Pharma Labs, Inc. has recently entered into an agreement with aclinical research organization (CRO) to begin clinical trials in India on OA-sys ,a new antiarthritic drug, in the treatment of osteo /infectious arthritis.
Global Pharma Labs, Inc. has also recently partnered with VDGPL in Zambia , which has now opened a wholesale pharmaceutical facility in Lusaka, Zambia.
We believe the anticipated merger by and between Labs and GPLL will offer benefit to the shareholders of both entities and will further distinguish both companies in the United States and internationally.
This press release contains forward-looking statements. There are risks and
uncertainties. The actual outcome of the anticipated merger could materially differ from that contemplated by management.
Recent GPLL News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/18/2023 04:09:25 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM